Veralox Therapeutics is focused on developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes, which each impact hundreds of thousands of new U.S. patients each year. Based on an understanding of the molecular mechanisms of these diseases, Veralox’s new treatment paradigms will lead to better outcomes for patients.
Company Led by University of Maryland Graduate Jeff Strovel Shows Continued Growth after Receiving Seed Funding from Maryland Momentum Fund and Other Investors in 2019
FREDERICK, Md.--(BUSINESS WIRE)--Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant…
The University of Maryland, Baltimore (UMB) strives to support the entrepreneurial talents of its students, faculty, staff, and alumni as it works to improve the human condition and serve the public…
Frederick Innovative Technology Center, Inc. (FITCI) is announcing the release of these startups' stories
Veralox Therapeutics, Inc., a preclinical stage therapeutics company located in Frederick, MD has received a $500,000 investment from the University System of Maryland (USM) Maryland Momentum Fund as…
Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes Veralox Therapeutics (“Veralox”), a preclinical stage company focused on accelerating…